Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer.
about
The two faces of Janus kinases and their respective STATs in mammary gland development and cancerProlactin regulation of the prostate gland: a female player in a male game.JAK2 inhibition for the treatment of hematologic and solid malignancies.Androgen metabolism and JAK/STAT pathway genes and prostate cancer risk.
P2860
Activating mutation (V617F) in the tyrosine kinase JAK2 is absent in locally-confined or castration-resistant prostate cancer.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Activating mutation (V617F) in ...... ion-resistant prostate cancer.
@en
Activating mutation
@nl
type
label
Activating mutation (V617F) in ...... ion-resistant prostate cancer.
@en
Activating mutation
@nl
prefLabel
Activating mutation (V617F) in ...... ion-resistant prostate cancer.
@en
Activating mutation
@nl
P2093
P1433
P1476
Activating mutation (V617F) in ...... tion-resistant prostate cancer
@en
P2093
Kalle Alanen
Marja T Nevalainen
Tina Bocker Edmonston
Xian-Hua Zhu
P356
10.1155/2010/610974
10.3233/ACP-CLO-2010-0534
P577
2010-01-01T00:00:00Z